{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-000660","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.286452+00:00","generated_at":"2026-06-06T09:58:59.021499+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CNS Pharma raises $3.7M in $0.30/unit offering; appoints Amy Mahery to board","bullets":["Offering of 2.2M shares, 11.1M pre-funded warrants, and 26.7M Series A & B warrants at $0.30 per unit.","Gross proceeds ~$3.7M; net proceeds to fund CNS-201 trial and working capital.","Amy Mahery appointed independent director as of Feb 1, 2024; Andrzej Andraczke resigned.","Warrant amendment for 3.756M existing warrants: exercise price reduced to $0.30 if shareholder approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-000660","json":"https://secwatch.observer/filing/0001683168-24-000660.json","markdown":"https://secwatch.observer/filing/0001683168-24-000660.md","text":"https://secwatch.observer/filing/0001683168-24-000660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:58:59.021499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4eaada4f0c","claim":"Amy Mahery was appointed as Independent Director at CNS Pharmaceuticals, Inc..","evidence_excerpt":"As previously reported, on January 17, 2024, the Company’s Board of Directors (the “Board”) agreed to appoint Amy Mahery as an independent member of the Company’s Board effective upon the completion of the Company’s financing.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"},{"claim_id":"65d2ee42635f8645fb139c53319178fe37ad306d","claim":"CNS Pharmaceuticals, Inc. entered into Placement Agreement with A.G.P./Alliance Global Partners and Maxim Group LLC valued at $3.7 million (effective 2024-01-29).","evidence_excerpt":"On January 29, 2024, the Company entered into a placement agency agreement with A.G.P./Alliance Global Partners (“AGP”) and Maxim Group LLC (“Maxim” and collectively with AGP, the “Placement Agents”) (the “Placement Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners and Maxim Group LLC"},{"label":"Value","value":"$3.7 million"},{"label":"Effective","value":"2024-01-29"}],"fact_type":"material_agreement"},{"claim_id":"baedc8e910ea1995d62e8ddd722ccff671b6ddcd","claim":"CNS Pharmaceuticals, Inc. amended Warrant Amendment (effective 2024-01-29).","evidence_excerpt":"anuary 29, 2024, the Company entered into a warrant amendment agreement (the “Warrant Amendment”) pursuant to which the Company","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Effective","value":"2024-01-29"}],"fact_type":"material_agreement"},{"claim_id":"f850e3d7089554b797579c6cf68de269c24193db","claim":"CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors (effective 2024-01-29).","evidence_excerpt":"the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors that participated in the offering","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Effective","value":"2024-01-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}